Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Michigan Spin-Off Signs With Medivation
by Michael McCoy
May 5, 2014
| A version of this story appeared in
Volume 92, Issue 18
OncoFusion Therapeutics, an oncology drug company formed in 2012 by two University of Michigan professors, has signed a licensing agreement with the San Francisco-based biotech firm Medivation. The deal gives Medivation rights to develop and commercialize compounds discovered by OncoFusion that target bromodomain and extraterminal proteins, which regulate genes and play a role in cancer. Medivation is involved in a lawsuit with professors from the University of California, Los Angeles, over a similar compound licensing agreement (C&EN, April 21, page 8).
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter